Eric Furman, Ph.D.

12790 El Camino Real
San Diego, CA 92130
Tel: 858-836-9000
Fax: 858-836-9001
Email:

Legal Areas of Emphasis

Patents

Freedom to Operate Analysis

Right to Practice Opinions

Licensing

Intellectual Property Due Diligence

Trade Secrets

Trademarks

Technical Areas of Emphasis

Biotechnology

Eukaryotic and Prokaryotic Systems

Virology

Immunology

Protein Purification and Characterization

Genomics

Genetically Modified Plants

Diagnostics

Cell-based Therapeutics

Medical Devices

Cosmetics

Dietary Supplements

CleanTech

Professional Profile

Eric S. Furman, Ph.D. is a partner in our San Diego office.  He specializes in patent protection and other forms of intellectual property protection for biotechnology, pharmaceuticals, and medical devices.

Dr. Furman’s practice includes strategic patent counseling and procurement, freedom to operate analysis, counseling on infringement and invalidity issues, licensing, and due diligence studies as related to negotiations for mergers and acquisitions.

Dr. Furman currently represents clients with technology in the fields of genetically modified plants and organisms, stem cells, pharmaceuticals, vaccines, dietary supplements, diagnostics, cleantech, and cosmetics.

Prior to joining the firm, Dr. Furman was a research assistant in the laboratory of Dr. Leroy Hood where he made transgenic mice with aberrant forms of myelin basic protein.  As a graduate student at the University of California, Los Angeles Medical School, he characterized transcription and splicing complexes, and was a teaching assistant for Donald S. Chisum, author of the preeminent treatise on patent law, while at law school.

Dr. Furman joined the firm in 1998 and became a partner in 2004.

Education

University of Washington, Seattle (J.D. 1998)

University of California, Los Angeles Medical School, Department of Biological Chemistry (Ph.D. Biochemistry 1995)

University of New Mexico (B.S. Biology 1988) summa cum laude

Representative Patents

7,727,715: Global gene expression analysis of human bronchial epithelial cells exposed    to cigarette smoke, smoke condensates, or components thereof

7,678,569:  Cloned genome of infectious hepatitis C virus strain HCV -TN and uses thereof

7,662,565:  Approaches to identify less harmful tobacco and tobacco products

7,566,812:  Transgenic mouse models of hepatitis C virus (HCV) and identification of HCV therapeutics

7,390,484:  Self-contained adipose derived stem cell processing unit

7,318,926:  Glycosylated Specificity Exchangers

7,022,830:  Hepatitis C virus codon optimized non-structural NS3/4A fusion gene

7,012,129:  Antiviral composition comprising glycine amide

6,743,626:  Artificial Salivary Gland

6,852,686:  Methods for ameliorating Icthyosiform skin diseases

6,660,842:  Ligand exchangers/receptor specificity exchangers that redirect antibodies to receptors on a Pathogen

6,680,059:  Vaccines containing ribavirin and methods of use thereof

6,759,056:  Mixture for transdermal delivery of low and high molecular weight compounds

6,919,612:  Use of parvovirus capsid particles in the inhibition of cell proliferation and migration

6,907,887:  Modifying nicotine and nitrosamine levels in tobacco

6,495,674:  Evectins and their use

6,448,794:  Apparatus and method for high throughput electrorotation analysis

6,417,324:  Synthetic peptides that bind to the hepatitis B virus core and E antigens

6,048,891:  Use of gamma tocopherol and its oxidative meta metabolite LLU-α in the treatment of natriuretic disease

Admissions/Qualifications

State Bar of California

Registered to practice before the U.S. Patent and Trademark Office

Articles, Speeches & Seminars

Eric Furman and Mark Marsden. “Focused Patent Strategies, Collaborations, and Drug Development Provide Security to Generate Financing.” The Scientist, June 19, 2008.

Lecturer at a seminar entitled ““Developing an intellectual property program in an increasingly competitive biotech market,” Genetic Engineering News Theatre at BIO 2008 in San Diego, California.

Lecturer at a seminar entitled “Implementing a Global Patent Strategy in a Rapidly Changing World,” Intasma User Forum, September 27, 2007. Mälmo, Sweden.

Lecturer at a seminar entitled “Approaching Intellectual Property Protection For Biotech Companies in an Increasingly Competitive Market,” Center for Molecular Medicine, Karolinska University Hospital, May 31, 2007, Stockholm, Sweden.

Eric Furman.  “Approaching Intellectual Property Protection for Biotech Companies in an Increasingly Competitive Market” Strategic Patent Protection, Reed Logic Books, 2006.

Eric Furman.  “Counseling Biotech Companies in the Competitive Market: The Interplay Between Freedom to Operate and Patent Protection” Winning Legal Strategies for Biotech Companies, Aspatore Books, 2005.

Lecturer at a seminar entitled “Strategies for Obtaining Broad, Enforceable Protection for Biotech and Medical Inventions in the United States and Abroad” April 30, 1999, Menlo Park, California.

Eric Furman. “The Role of Expert Testimony in Patent Litigation in the United States” International Symposium on Intellectual Property and the Management of International Disputes, Kyushu University, Fukuoka, Japan (September 12-14, 1996): 1-18.

Eric Furman and Dohn Glitz. 1995. “Purification of Spliceosome A-Complex and its Visualization by Electron Microscapy” Journal of Biological Chemistry (270):15515-15522.

Eric Furman and Dohn Glitz. 1995. “Purification of the A-Complex Spliceosome its Characterization by Electron Microscopy and the Localization of the 5’ Segment of the U2 SnRNA in the Particle” RNA Processing Conference, Cold Spring Harbor, New York (Spring): 1999.

Yasuhiro Ohashi, Joshua Brickman, Eric Furman, Blake Middleton, and Michael Carrey. 1994. “Modulating the Potency of an Activator in a Yeast in vitro Transcription System” Molecular and Cellular Biology (14):2731-2739.